

# Bradley A Maron

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5642744/bradley-a-maron-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

101  
papers

3,381  
citations

31  
h-index

56  
g-index

125  
ext. papers

4,414  
ext. citations

8.5  
avg, IF

5.63  
L-index

#	Paper	IF	Citations
101	Tadalafil for veterans with chronic obstructive pulmonary disease-pulmonary hypertension: A multicenter, placebo-controlled randomized trial.. <i>Pulmonary Circulation</i> , <b>2022</b> , 12, e12043	2.7	0
100	Harnessing Big Data to Advance Treatment and Understanding of Pulmonary Hypertension.. <i>Circulation Research</i> , <b>2022</b> , 130, 1423-1444	15.7	3
99	Cardiovascular Diseases That Have Emerged From the Darkness. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e021095	6	3
98	Network medicine in Cardiovascular Research. <i>Cardiovascular Research</i> , <b>2021</b> , 117, 2186-2202	9.9	6
97	Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside. <i>Clinical Epigenetics</i> , <b>2021</b> , 13, 66	7.7	9
96	Integrating haemodynamics identifies an extreme pulmonary hypertension phenotype. <i>European Respiratory Journal</i> , <b>2021</b> , 58,	13.6	2
95	Outcomes of pulmonary vasodilator use in Veterans with pulmonary hypertension associated with left heart disease and lung disease. <i>Pulmonary Circulation</i> , <b>2021</b> , 11, 20458940211001714	2.7	1
94	Adjusting to the New Normal: Echocardiography to Find Pulmonary Hypertension. <i>EClinicalMedicine</i> , <b>2021</b> , 35, 100867	11.3	
93	Elevated pulmonary vascular resistance predicts mortality in COPD patients. <i>European Respiratory Journal</i> , <b>2021</b> , 58,	13.6	3
92	Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 1472-1487	10.2	13
91	NEDD9 Is a Novel and Modifiable Mediator of Platelet-Endothelial Adhesion in the Pulmonary Circulation. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 1533-1545	10.2	3
90	Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14,	7.6	1
89	Renin-Angiotensin-Aldosterone System Inhibitor Use and Mortality in Pulmonary Hypertension: Insights From the Veterans Affairs Clinical Assessment Reporting and Tracking Database. <i>Chest</i> , <b>2021</b> , 159, 1586-1597	5.3	4
88	Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes. <i>Nature Communications</i> , <b>2021</b> , 12, 873	17.4	18
87	Quantification of Arterial and Venous Morphologic Markers in Pulmonary Arterial Hypertension Using CT Imaging. <i>Chest</i> , <b>2021</b> , 160, 2220-2231	5.3	4
86	Chronic Thromboembolic Pulmonary Hypertension: the Bench. <i>Current Cardiology Reports</i> , <b>2021</b> , 23, 1414.2		1
85	Chronic Thromboembolic Pulmonary Hypertension: the Bedside. <i>Current Cardiology Reports</i> , <b>2021</b> , 23, 147	4.2	1

84	Mildly elevated pulmonary artery systolic pressure on echocardiography: bridging the gap in current guidelines. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 1185-1191	35.1	2
83	Usefulness of ventilatory inefficiency in predicting prognosis across the heart failure spectrum.. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7	1
82	Factors Associated With Potentially Inappropriate Phosphodiesterase-5 Inhibitor Use for Pulmonary Hypertension in the United States, 2006 to 2015. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2020</b> , 13, e005993	5.8	4
81	Perspectives on Cardiopulmonary Critical Care for Patients With COVID-19: From Members of the American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e017111	6	4
80	The application of big data to cardiovascular disease: paths to precision medicine. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 29-38	15.9	34
79	Pulmonary arterial hypertension: Rationale for using multiple vs. single drug therapy. <i>Global Cardiology Science &amp; Practice</i> , <b>2020</b> , 2020, e202008	0.7	
78	Pulmonary arterial hypertension: Rationale for using multiple vs. single drug therapy. <i>Global Cardiology Science &amp; Practice</i> , <b>2020</b> , 2020, e202008	0.7	0
77	Inflammation, immunity, and vascular remodeling in pulmonary hypertension; Evidence for complement involvement?. <i>Global Cardiology Science &amp; Practice</i> , <b>2020</b> , 2020, e202001	0.7	8
76	Pulmonary arterial hypertension: Cellular and molecular changes in the lung. <i>Global Cardiology Science &amp; Practice</i> , <b>2020</b> , 2020, e202003	0.7	1
75	Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysis. <i>Journal of Heart and Lung Transplantation</i> , <b>2020</b> , 39, 289-299	5.8	10
74	Endothelin-1, cardiac morphology, and heart failure: the MESA angiogenesis study. <i>Journal of Heart and Lung Transplantation</i> , <b>2020</b> , 39, 45-52	5.8	5
73	Role of Pulmonary Artery Wedge Pressure Saturation During Right Heart Catheterization: A Prospective Study. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e007981	7.6	9
72	Claims-Based Algorithms for Identifying Patients With Pulmonary Hypertension: A Comparison of Decision Rules and Machine-Learning Approaches. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e016648	6	6
71	Cardiopulmonary Hemodynamics in Pulmonary Hypertension and Heart Failure: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 2671-2681	15.1	19
70	Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. <i>Lancet Respiratory Medicine</i> , <b>2020</b> , 8, 873-884	35.1	41
69	A global network for network medicine. <i>Npj Systems Biology and Applications</i> , <b>2020</b> , 6, 29	5	6
68	Impact of the New Pulmonary Hypertension Definition on Heart Transplant Outcomes: Expanding the Hemodynamic Risk Profile. <i>Chest</i> , <b>2020</b> , 157, 151-161	5.3	12
67	Immunoglobulin-driven Complement Activation Regulates Proinflammatory Remodeling in Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 201, 224-239	10.2	34

66	Association of Mild Echocardiographic Pulmonary Hypertension With Mortality and Right Ventricular Function. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 1112-1121	16.2	31
65	Back to the Future: Building Up the Case for Exploring Red Blood Cell Morphology in Pulmonary Arterial Hypertension. <i>Annals of the American Thoracic Society</i> , <b>2019</b> , 16, 548-550	4.7	1
64	Correspondence on the debate regarding the haemodynamic definition of pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	0
63	Moving Beyond the Sarcomere to Explain Heterogeneity in Hypertrophic Cardiomyopathy: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 1978-1986	15.1	59
62	A Concerning Trend for Patients With Pulmonary Hypertension in the Era of Evidence-Based Medicine. <i>Circulation</i> , <b>2019</b> , 139, 1861-1864	16.7	14
61	Isolating pulmonary microvascular endothelial cells ex vivo: Implications for pulmonary arterial hypertension, and a caution on the use of commercial biomaterials. <i>PLoS ONE</i> , <b>2019</b> , 14, e0211909	3.7	4
60	Mildly increased pulmonary arterial pressure: a new disease entity or just a marker of poor prognosis?. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1057-1061	12.3	6
59	Segmental Arterial Mediolytic: An Important but Often Overlooked Cause of Multi-Vessel Thrombosis. <i>American Journal of Medicine</i> , <b>2018</b> , 131, e231-e234	2.4	1
58	Association between Pulmonary Hypertension and Clinical Outcomes in Hospitalized Patients with Sickle Cell Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 534-537	10.2	2
57	Network Analysis to Risk Stratify Patients With Exercise Intolerance. <i>Circulation Research</i> , <b>2018</b> , 122, 864-876	15.7	29
56	H2 Receptor Antagonist Use and Mortality in Pulmonary Hypertension: Insight from the VA-CART Program. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 1638-1641	10.2	8
55	Redefining pulmonary hypertension. <i>Lancet Respiratory Medicine</i> , <b>2018</b> , 6, 168-170	35.1	26
54	Career Development of Young Physician-Scientists in the Cardiovascular Sciences: Perspective and Advice From the Early Career Committee of the Cardiopulmonary, Critical Care, and Resuscitation Council of the American Heart Association. <i>Circulation Research</i> , <b>2018</b> , 122, 1330-1333	15.7	5
53	NEDD9 targets to promote endothelial fibrosis and pulmonary arterial hypertension. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	52
52	Diagnostic Assessment of the Pulmonary Hypertension Patient. <i>Advances in Pulmonary Hypertension</i> , <b>2018</b> , 16, 112-119	0.5	
51	Mild Pulmonary Hypertension Is Associated With Increased Mortality: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7, e009729	6	34
50	MicroRNA Dysregulation in Pulmonary Arteries from Chronic Obstructive Pulmonary Disease. Relationships with Vascular Remodeling. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2018</b> , 59, 490-499	5.7	23
49	Reply: Can treprostinil-induced early gastrointestinal side effects serve as predictors of pulmonary arterial hypertension prognosis?. <i>International Journal of Cardiology</i> , <b>2018</b> , 264, 188	3.2	

48	Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10, e003689	7.6	28
47	Functional impact of exercise pulmonary hypertension in patients with borderline resting pulmonary arterial pressure. <i>Pulmonary Circulation</i> , <b>2017</b> , 7, 654-665	2.7	30
46	What's in a side effect? The association between pulmonary vasodilator adverse drug events and clinical outcomes in patients with pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , <b>2017</b> , 240, 386-391	3.2	6
45	Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 1361-1368	16.2	72
44	Thermodilution vs Estimated Fick Cardiac Output Measurement in Clinical Practice: An Analysis of Mortality From the Veterans Affairs Clinical Assessment, Reporting, and Tracking (VA CART) Program and Vanderbilt University. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 1090-1099	16.2	47
43	PVDOMICS: A Multi-Center Study to Improve Understanding of Pulmonary Vascular Disease Through Phenomics. <i>Circulation Research</i> , <b>2017</b> , 121, 1136-1139	15.7	58
42	Translational Advances in the Field of Pulmonary Hypertension. Focusing on Developmental Origins and Disease Inception for the Prevention of Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 292-301	10.2	32
41	Sex-based differences in veterans with pulmonary hypertension: Results from the veterans affairs-clinical assessment reporting and tracking database. <i>PLoS ONE</i> , <b>2017</b> , 12, e0187734	3.7	13
40	Genetic Misdiagnoses and the Potential for Health Disparities. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 655-65	59.2	394
39	Pulmonary vascular and ventricular dysfunction in the susceptible patient (2015 Grover Conference series). <i>Pulmonary Circulation</i> , <b>2016</b> , 6, 426-438	2.7	4
38	Diagnosis, Treatment, and Clinical Management of Pulmonary Arterial Hypertension in the Contemporary Era: A Review. <i>JAMA Cardiology</i> , <b>2016</b> , 1, 1056-1065	16.2	71
37	Up-regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension. <i>FASEB Journal</i> , <b>2016</b> , 30, 2511-27	0.9	28
36	Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. <i>Circulation</i> , <b>2016</b> , 133, 1240-8	16.7	167
35	Relation of Doppler Tissue Imaging Parameters With Heart Failure Progression in Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 1808-14	3	9
34	Elevated pulmonary arterial and systemic plasma aldosterone levels associate with impaired cardiac reserve capacity during exercise in left ventricular systolic heart failure patients: A pilot study. <i>Journal of Heart and Lung Transplantation</i> , <b>2016</b> , 35, 342-351	5.8	10
33	Intratracheal Gene Delivery of SERCA2a Ameliorates Chronic Post-Capillary Pulmonary Hypertension: A Large Animal Model. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 2032-46	15.1	48
32	Hemodynamics should be the primary approach to diagnosing, following, and managing pulmonary arterial hypertension. <i>Canadian Journal of Cardiology</i> , <b>2015</b> , 31, 515-20	3.8	7
31	Building the case for novel clinical trials in pulmonary arterial hypertension. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2015</b> , 8, 114-23	5.8	14

30	Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension: Part II: Neurohormonal Signaling Contributes to the Pulmonary Vascular and Right Ventricular Pathophenotype of Pulmonary Arterial Hypertension. <i>Circulation</i> , <b>2015</b> , 131, 2079-91	16.7	61
29	Protocol for exercise hemodynamic assessment: performing an invasive cardiopulmonary exercise test in clinical practice. <i>Pulmonary Circulation</i> , <b>2015</b> , 5, 610-8	2.7	53
28	Echocardiographic predictors of mortality in patients with pulmonary hypertension and cardiopulmonary comorbidities. <i>PLoS ONE</i> , <b>2015</b> , 10, e0119277	3.7	13
27	Towards widespread noninvasive assessment of pulmonary vascular resistance in clinical practice. <i>Journal of the American Society of Echocardiography</i> , <b>2014</b> , 27, 108-9	5.8	4
26	Upregulation of steroidogenic acute regulatory protein by hypoxia stimulates aldosterone synthesis in pulmonary artery endothelial cells to promote pulmonary vascular fibrosis. <i>Circulation</i> , <b>2014</b> , 130, 168-79	16.7	41
25	The heterogeneity of clinical practice patterns among an international cohort of pulmonary arterial hypertension experts. <i>Pulmonary Circulation</i> , <b>2014</b> , 4, 441-51	2.7	27
24	Emerging hemodynamic signatures of the right heart (Third International Right Heart Failure Summit, part 2). <i>Pulmonary Circulation</i> , <b>2014</b> , 4, 705-16	2.7	1
23	Explaining unexplained dyspnea: the ever "holesome" heart. <i>Circulation</i> , <b>2014</b> , 130, 2057-66	16.7	5
22	The role of the renin-angiotensin-aldosterone system in the pathobiology of pulmonary arterial hypertension (2013 Grover Conference series). <i>Pulmonary Circulation</i> , <b>2014</b> , 4, 200-10	2.7	74
21	Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials). <i>American Journal of Cardiology</i> , <b>2013</b> , 112, 720-5	3	79
20	S-nitrosothiols and the S-nitrosoproteome of the cardiovascular system. <i>Antioxidants and Redox Signaling</i> , <b>2013</b> , 18, 270-87	8.4	69
19	Study design and rationale for investigating phosphodiesterase type 5 inhibition for the treatment of pulmonary hypertension due to chronic obstructive lung disease: the TADA-PHiLD (TADAlafil for Pulmonary Hypertension associated with chronic obstructive Lung Disease) trial. <i>Pulmonary Circulation</i> , <b>2013</b> , 3, 688-97	2.7	8
18	Clinical profile and underdiagnosis of pulmonary hypertension in US veteran patients. <i>Circulation: Heart Failure</i> , <b>2013</b> , 6, 906-12	7.6	45
17	The invasive cardiopulmonary exercise test. <i>Circulation</i> , <b>2013</b> , 127, 1157-64	16.7	90
16	Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 277-83 <sup>12,3</sup>		74
15	Pulmonary hypertension: pathophysiology and signaling pathways. <i>Handbook of Experimental Pharmacology</i> , <b>2013</b> , 218, 31-58	3.2	16
14	Raptor activation by aldosterone promotes apoptosis resistance in pulmonary artery smooth muscle cells to modulate adverse pulmonary vascular remodeling in pulmonary arterial hypertension. <i>FASEB Journal</i> , <b>2013</b> , 27, 1199.1	0.9	1
13	Aldosterone Activates Autophagy To Increase Fibroblast Collagen Synthesis and Vascular Stiffness. <i>FASEB Journal</i> , <b>2013</b> , 27, 1188.9	0.9	

12	Subcellular localization of oxidants and redox modulation of endothelial nitric oxide synthase. <i>Circulation Journal</i> , <b>2012</b> , 76, 2497-512	2.9	50
11	MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. <i>Circulation</i> , <b>2012</b> , 125, 1520-32	16.7	207
10	Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. <i>Circulation</i> , <b>2012</b> , 126, 963-74	16.7	141
9	Protocol for vasoreactivity testing with epoprostenol in pulmonary hypertension. <i>Critical Pathways in Cardiology</i> , <b>2012</b> , 11, 40-2	1.3	6
8	Paradoxical embolism. <i>Circulation</i> , <b>2010</b> , 122, 1968-72	16.7	22
7	Aldosterone receptor antagonists: effective but often forgotten. <i>Circulation</i> , <b>2010</b> , 121, 934-9	16.7	65
6	Aldosterone increases oxidant stress to impair guanylyl cyclase activity by cysteinyl thiol oxidation in vascular smooth muscle cells. <i>Journal of Biological Chemistry</i> , <b>2009</b> , 284, 7665-72	5.4	82
5	The treatment of hyperhomocysteinemia. <i>Annual Review of Medicine</i> , <b>2009</b> , 60, 39-54	17.4	195
4	Mineralocorticoid receptor antagonists and endothelial function. <i>Current Opinion in Investigational Drugs</i> , <b>2008</b> , 9, 963-9		11
3	Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. <i>Nature Medicine</i> , <b>2007</b> , 13, 189-97	50.5	269
2	Should hyperhomocysteinemia be treated in patients with atherosclerotic disease?. <i>Current Atherosclerosis Reports</i> , <b>2007</b> , 9, 375-83	6	15
1	Homocysteine. <i>Clinics in Laboratory Medicine</i> , <b>2006</b> , 26, 591-609, vi	2.1	16